{"id":"treatment-withdrawal","safety":{"commonSideEffects":[{"rate":"10-30%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Insomnia"},{"rate":"5-15%","effect":"Anxiety"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Withdrawal treatment typically involves a combination of medications and behavioral therapies to help manage symptoms such as anxiety, insomnia, and cravings. Medications such as buprenorphine, methadone, and naltrexone are commonly used to help manage withdrawal symptoms and prevent relapse.","oneSentence":"Withdrawal treatment involves the use of medications to help manage withdrawal symptoms in individuals who are dependent on substances such as opioids, alcohol, or benzodiazepines.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:03.349Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Management of opioid withdrawal symptoms"},{"name":"Prevention of opioid relapse"}]},"trialDetails":[{"nctId":"NCT07483983","phase":"PHASE2","title":"Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2026-03","conditions":"Metastatic/Locally Advanced Non-Small-Cell Lung Cancer, Metastatic/Locally Pancreatic Ductal Adenocarcinoma","enrollment":60},{"nctId":"NCT06902246","phase":"PHASE2","title":"Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"University of Miami","startDate":"2026-05-01","conditions":"Unresectable Hepatocellular Carcinoma, Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT05711615","phase":"PHASE1","title":"Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-02-06","conditions":"Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma, Metastatic Myxofibrosarcoma","enrollment":30},{"nctId":"NCT07172919","phase":"PHASE2","title":"A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation","status":"RECRUITING","sponsor":"Amgen","startDate":"2026-01-02","conditions":"Advanced Solid Tumors","enrollment":14},{"nctId":"NCT05226117","phase":"PHASE2","title":"Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer","status":"COMPLETED","sponsor":"IRCCS San Raffaele","startDate":"2022-03-23","conditions":"Urothelial Carcinoma","enrollment":44},{"nctId":"NCT07296094","phase":"PHASE2","title":"Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder","status":"NOT_YET_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-05-01","conditions":"Alcohol Use Disorder","enrollment":36},{"nctId":"NCT05063565","phase":"PHASE2","title":"TheraSphere With Durvalumab and Tremelimumab for HCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Scientific Corporation","startDate":"2023-11-03","conditions":"Hepatocellular Carcinoma","enrollment":100},{"nctId":"NCT07494448","phase":"PHASE1, PHASE2","title":"Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"MedSIR","startDate":"2026-07-01","conditions":"HER 2 Positive Advanced Breast Cancer, Breast Cancer","enrollment":24},{"nctId":"NCT04660344","phase":"PHASE3","title":"A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-05-03","conditions":"Muscle-invasive Bladder Cancer","enrollment":761},{"nctId":"NCT03410992","phase":"PHASE3","title":"A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2018-02-05","conditions":"Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis","enrollment":435},{"nctId":"NCT05068440","phase":"PHASE2","title":"Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib","status":"COMPLETED","sponsor":"BeiGene","startDate":"2021-08-11","conditions":"Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma","enrollment":65},{"nctId":"NCT04670679","phase":"PHASE1","title":"A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Erasca, Inc.","startDate":"2020-12-15","conditions":"Advanced or Metastatic Solid Tumors","enrollment":90},{"nctId":"NCT07491913","phase":"NA","title":"Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission","status":"RECRUITING","sponsor":"Marmara University","startDate":"2025-06-15","conditions":"Takayasu Arteritis","enrollment":40},{"nctId":"NCT04221204","phase":"PHASE1","title":"A Monotherapy in Subjects With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"3D Medicines (Beijing) Co., Ltd.","startDate":"2019-09-01","conditions":"Solid Tumor, Adult","enrollment":42},{"nctId":"NCT06863272","phase":"PHASE1, PHASE2","title":"A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-03","conditions":"Castration-Resistant Prostatic Cancer, Metastasis","enrollment":360},{"nctId":"NCT07493252","phase":"NA","title":"A Behavioral Application for Improving Smoking Cessation Among Smokers","status":"NOT_YET_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2026-08-01","conditions":"Cigarette Smoking-Related Carcinoma","enrollment":1812},{"nctId":"NCT06441604","phase":"PHASE2","title":"Extended-release Buprenorphine as a Novel Low-dose Induction Strategy","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2025-10-27","conditions":"Opioid Use Disorder","enrollment":30},{"nctId":"NCT07493785","phase":"PHASE2, PHASE3","title":"Dexmedetomidine for Invasive Ventilation In the NEOnate","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Intercommunal Creteil","startDate":"2026-06-01","conditions":"Invasive Ventilation, Infant Pain, Infant Discomfort","enrollment":246},{"nctId":"NCT07123883","phase":"NA","title":"Dry Needling for Temporomandibular Disorder","status":"COMPLETED","sponsor":"Atlas University","startDate":"2025-07-28","conditions":"TMD/Orofacial Pain, Muscle Spasm","enrollment":40},{"nctId":"NCT07489352","phase":"NA","title":"N-of-1 Trial to Promote Beta-Blocker Titration in Heart Failure","status":"NOT_YET_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-05-05","conditions":"Heart Failure, Beta-blocker, Older Adults","enrollment":50},{"nctId":"NCT07235293","phase":"PHASE2","title":"A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.","status":"RECRUITING","sponsor":"Kahr Bio Australia Pty Ltd","startDate":"2026-01-16","conditions":"Colorectal Cancer","enrollment":90},{"nctId":"NCT07221786","phase":"NA","title":"Preoperative Opioid Tapering Before Spine Surgery","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2025-12-01","conditions":"Opioid Consumption, Postoperative, Pain After Surgery, Opioid Dependency","enrollment":45},{"nctId":"NCT07489547","phase":"PHASE2, PHASE3","title":"Medication Withdrawal in Stable HF With Improved LVEF","status":"RECRUITING","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2025-03-01","conditions":"Heart Failure","enrollment":90},{"nctId":"NCT07300514","phase":"PHASE3","title":"Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-03-30","conditions":"Maintenance Treatment of Peripheral T-cell Lymphoma","enrollment":136},{"nctId":"NCT04008797","phase":"PHASE1, PHASE2","title":"A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eisai Inc.","startDate":"2019-07-11","conditions":"Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular","enrollment":301},{"nctId":"NCT01581554","phase":"","title":"Withdrawal of Therapy After Long-Term Antiviral Treatment for Chronic Hepatitis B","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2011-05-18","conditions":"Chronic Hepatitis B e Antigen Positive, Chronic Hepatitis B e Antigen Negative","enrollment":15},{"nctId":"NCT06667076","phase":"PHASE2","title":"A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-12-16","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":480},{"nctId":"NCT05030038","phase":"","title":"Oral Aromatase Inhibitors Modify the Gut Microbiome","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2022-03-29","conditions":"Breast Cancer","enrollment":25},{"nctId":"NCT07487519","phase":"PHASE2","title":"Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2026-04-25","conditions":"Breast Cancer (Triple Negative Breast Cancer (TNBC))","enrollment":180},{"nctId":"NCT07488884","phase":"PHASE1","title":"Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2026-03-01","conditions":"Pancreatic Cancer Resectable, Pancreatic Cancer","enrollment":30},{"nctId":"NCT06399653","phase":"NA","title":"Non-invasive Vagal Nerve Stimulation as Novel Treatment to Improve Functional Outcomes in Veterans With Alcohol Use Disorder","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2025-01-01","conditions":"Alcohol Use Disorder","enrollment":80},{"nctId":"NCT07488572","phase":"PHASE2","title":"Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study","status":"ENROLLING_BY_INVITATION","sponsor":"Sun Yat-sen University","startDate":"2025-11-01","conditions":"Renal Cell Carcinoma (RCC), Metastatic Clear Cell Renal Cell Carcinoma","enrollment":60},{"nctId":"NCT05595577","phase":"NA","title":"Improving Exercise Capacity With a Tailored Physical Activity Intervention","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2023-03-01","conditions":"Non Hodgkin Lymphoma, Heart; Functional Disturbance, Hodgkin Lymphoma","enrollment":110},{"nctId":"NCT07484217","phase":"PHASE3","title":"Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol","status":"RECRUITING","sponsor":"Axsome Therapeutics, Inc.","startDate":"2026-02-23","conditions":"Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms","enrollment":508},{"nctId":"NCT07363720","phase":"PHASE3","title":"A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy","status":"RECRUITING","sponsor":"Takeda","startDate":"2026-01-29","conditions":"Narcolepsy Type 1 (NT1), Narcolepsy With Cataplexy","enrollment":88},{"nctId":"NCT06976632","phase":"NA","title":"Effect of Helfer Skin Tap and Cold Application on Pain and Hemodynamics During Vaccination","status":"RECRUITING","sponsor":"Celal Bayar University","startDate":"2025-05-09","conditions":"Pregnant Women","enrollment":90},{"nctId":"NCT06842498","phase":"PHASE2","title":"A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","status":"RECRUITING","sponsor":"Kyntra Bio","startDate":"2026-02-22","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":75},{"nctId":"NCT07294508","phase":"PHASE2, PHASE3","title":"A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2026-02-27","conditions":"HER2 + Breast Cancer","enrollment":706},{"nctId":"NCT05029141","phase":"PHASE2","title":"New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2021-09-01","conditions":"Acute Myeloid Leukemia, Refractory Acute Leukemia, Relapsed Adult AML","enrollment":21},{"nctId":"NCT07482059","phase":"PHASE1, PHASE2","title":"A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2026-02","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":33},{"nctId":"NCT04083976","phase":"PHASE2","title":"A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-11-20","conditions":"Advanced Solid Tumor","enrollment":316},{"nctId":"NCT03491683","phase":"PHASE1, PHASE2","title":"INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Inovio Pharmaceuticals","startDate":"2018-05-31","conditions":"Glioblastoma","enrollment":52},{"nctId":"NCT03390504","phase":"PHASE3","title":"A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-03-23","conditions":"Urothelial Cancer","enrollment":629},{"nctId":"NCT07483970","phase":"PHASE1","title":"A Phase I/II Study of JL19001 Injection Alone or in Combination With BCG in Subjects With High Risk Non-Muscle Invasive Bladder Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Jecho Biopharmaceuticals Co., Ltd.","startDate":"2026-03-30","conditions":"High Risk Non-muscle Invasive Bladder Cancer","enrollment":18},{"nctId":"NCT07405164","phase":"PHASE3","title":"Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-03-23","conditions":"Von Hippel-Lindau Disease, Carcinoma, Renal Cell","enrollment":450},{"nctId":"NCT03596645","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-10-29","conditions":"Colitis, Ulcerative","enrollment":84},{"nctId":"NCT03793361","phase":"PHASE2","title":"Phase II Study of Regorafenib as Maintenance Therapy","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2019-05-15","conditions":"Metastatic Soft Tissue Sarcoma","enrollment":127},{"nctId":"NCT07205822","phase":"PHASE3","title":"A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-10-30","conditions":"Breast Cancer","enrollment":100},{"nctId":"NCT07454642","phase":"PHASE1","title":"AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors","status":"RECRUITING","sponsor":"Avacta Life Sciences Ltd","startDate":"2026-03","conditions":"Vulvar Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, Gastric Adenocarcinoma","enrollment":144},{"nctId":"NCT07270770","phase":"PHASE1","title":"BY002 IIT Study in R/R Acute Leukemia","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-03-15","conditions":"Acute Leukemia, KMT2A Rearrangements or NPM1 Mutations Acute Leukemia","enrollment":18},{"nctId":"NCT03301220","phase":"PHASE3","title":"A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2017-11-07","conditions":"Smoldering Multiple Myeloma","enrollment":390},{"nctId":"NCT07052162","phase":"PHASE4","title":"Investigating the Pharmacokinetics of Tafenoquine in Healthy Papua New Guinean Children","status":"RECRUITING","sponsor":"Curtin University","startDate":"2025-10-20","conditions":"Pharmacokinetics of Tafenoquine","enrollment":30},{"nctId":"NCT05889494","phase":"NA","title":"Autologous Whole Blood Management for Transfusion Reduction in Adult Cardiac Surgery Patients","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2025-03-24","conditions":"Postoperative Hemorrhage, Postoperative Anemia, Postoperative Blood Loss","enrollment":64},{"nctId":"NCT05100862","phase":"PHASE3","title":"A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma","status":"RECRUITING","sponsor":"BeiGene","startDate":"2022-03-10","conditions":"Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma","enrollment":780},{"nctId":"NCT02838420","phase":"PHASE3","title":"A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2016-08-03","conditions":"Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer","enrollment":187},{"nctId":"NCT07221396","phase":"NA","title":"LDART for Stimulant Use Disorder","status":"NOT_YET_RECRUITING","sponsor":"Yale University","startDate":"2026-04-01","conditions":"Stimulant Use Disorder, Cocaine Use Disorder, Methamphetamine Use Disorder","enrollment":80},{"nctId":"NCT04077463","phase":"PHASE1","title":"A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-09-04","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":701},{"nctId":"NCT05694715","phase":"PHASE1","title":"Combination Therapy in Cancers With Mutations in DNA Repair Genes","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2023-05-23","conditions":"Metastatic Solid Tumor, BRCA1 Mutation, BRCA2 Mutation","enrollment":24},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT06531876","phase":"","title":"Efficacy of the Dreem 3S Ambulatory Sleep Monitoring Device for the Evaluation of Narcolepsy","status":"COMPLETED","sponsor":"Beacon Biosignals","startDate":"2024-07-01","conditions":"Narcolepsy Type 1, Hypersomnia, Sleep Disorder","enrollment":78},{"nctId":"NCT06650748","phase":"PHASE2","title":"Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Peking University","startDate":"2025-05-01","conditions":"Breast Cancer, Early-stage Breast Cancer","enrollment":100},{"nctId":"NCT07474064","phase":"PHASE2","title":"Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC","status":"NOT_YET_RECRUITING","sponsor":"chenxu","startDate":"2026-03-26","conditions":"Muscle Invasive Bladder Cancer (MIBC)","enrollment":146},{"nctId":"NCT04531917","phase":"NA","title":"The Effect of Pain Neuroscience Education and Behavioural Graded Activity on Chronic Pain in Breast Cancer Survivors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2020-10-12","conditions":"Breast Neoplasms, Survivors, Chronic Pain","enrollment":122},{"nctId":"NCT05081999","phase":"PHASE4","title":"De-Adoption of Beta-Blockers in Patients With Stable Ischemic Heart Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alberta","startDate":"2023-01-30","conditions":"Stable Ischemic Heart Disease, Coronary Artery Disease, Beta-blocker Therapy","enrollment":59},{"nctId":"NCT05309655","phase":"NA","title":"Cardiac Outcomes With Near-Complete Estrogen Deprivation","status":"RECRUITING","sponsor":"Duke University","startDate":"2022-09-02","conditions":"Breast Cancer, Triple Negative Breast Cancer, Cardiovascular Complications","enrollment":90},{"nctId":"NCT06894771","phase":"PHASE1","title":"A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-23","conditions":"Malignant Neoplasm","enrollment":5},{"nctId":"NCT07246902","phase":"","title":"Mobilization and Outcomes After Venous Closure","status":"RECRUITING","sponsor":"Cordis US Corp.","startDate":"2025-11-24","conditions":"Venous Vascular Closure, Electrophysiology Study","enrollment":300},{"nctId":"NCT06095115","phase":"PHASE3","title":"A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-10-12","conditions":"Plaque Psoriasis","enrollment":684},{"nctId":"NCT07396545","phase":"NA","title":"External Oblique Intercostal Block Versus Erector Spinae Plane Block on Postoperative Pain in Laparoscopic Radical Gastrectomy","status":"RECRUITING","sponsor":"General Hospital of Ningxia Medical University","startDate":"2026-03-12","conditions":"Postoperative Pain","enrollment":184},{"nctId":"NCT03643510","phase":"PHASE2","title":"Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-08-21","conditions":"Adenocarcinoma of Endometrium","enrollment":28},{"nctId":"NCT03911466","phase":"","title":"Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study","status":"COMPLETED","sponsor":"T. John Winhusen, PhD","startDate":"2020-07-21","conditions":"Opioid-Related Disorders, Drug Addiction, Pregnancy Related","enrollment":97},{"nctId":"NCT03911739","phase":"","title":"Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study","status":"COMPLETED","sponsor":"T. John Winhusen, PhD","startDate":"2021-06-14","conditions":"Opioid-Related Disorders, Drug Addiction, Pregnancy Related","enrollment":71},{"nctId":"NCT05230810","phase":"PHASE1, PHASE2","title":"Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Criterium, Inc.","startDate":"2022-08-25","conditions":"HER2-positive Metastatic Breast Cancer","enrollment":40},{"nctId":"NCT07472478","phase":"PHASE2","title":"Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2026-03-15","conditions":"Lung Cancer (NSCLC), KRAS G12C Lung Cancer","enrollment":32},{"nctId":"NCT07475728","phase":"","title":"EMS-Initiated Buprenorphine","status":"NOT_YET_RECRUITING","sponsor":"Yale University","startDate":"2026-03","conditions":"Opioid Use Disorder","enrollment":495},{"nctId":"NCT04108208","phase":"PHASE4","title":"A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-12-17","conditions":"Prostatic Neoplasms","enrollment":75},{"nctId":"NCT04181827","phase":"PHASE3","title":"A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2020-06-12","conditions":"Multiple Myeloma","enrollment":419},{"nctId":"NCT06741969","phase":"PHASE3","title":"Nipocalimab in Moderate to Severe Sjogren's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-12-04","conditions":"Sjogrens Syndrome","enrollment":655},{"nctId":"NCT07320586","phase":"PHASE2","title":"Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Shandong Tumor Hospital","startDate":"2021-03-01","conditions":"Gastric Cancer, Second-line Therapy","enrollment":40},{"nctId":"NCT05853367","phase":"PHASE1","title":"Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-07-06","conditions":"Metastatic Solid Tumors, Advanced Solid Tumors","enrollment":178},{"nctId":"NCT07463235","phase":"PHASE3","title":"Safety and Potency of a High Cabergoline Dosage in Microprolactinomas","status":"RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-03-04","conditions":"Prolactinoma, Prolactin Excess","enrollment":70},{"nctId":"NCT05179876","phase":"PHASE3","title":"A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option","status":"RECRUITING","sponsor":"Actelion","startDate":"2022-05-04","conditions":"Hypertension, Pulmonary","enrollment":280},{"nctId":"NCT05862012","phase":"PHASE1","title":"Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)","status":"RECRUITING","sponsor":"Ichnos Sciences SA","startDate":"2023-11-01","conditions":"Relapsed/Refractory Multiple Myeloma","enrollment":200},{"nctId":"NCT07459608","phase":"PHASE2","title":"Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2026-03-10","conditions":"Indolent Lymphoma, WM, MZL","enrollment":75},{"nctId":"NCT06008288","phase":"PHASE2","title":"A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.","status":"RECRUITING","sponsor":"Allist Pharmaceuticals, Inc.","startDate":"2023-10-27","conditions":"KRAS P.G12C, Pancreatic Cancer, Solid Tumor","enrollment":88},{"nctId":"NCT05567185","phase":"PHASE1","title":"A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2023-03-03","conditions":"Urinary Bladder Neoplasms, Receptors, Fibroblast Growth Factor","enrollment":5},{"nctId":"NCT04666610","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy","status":"ACTIVE_NOT_RECRUITING","sponsor":"UCB Biopharma SRL","startDate":"2021-07-29","conditions":"Childhood Absence Epilepsy, Juvenile Absence Epilepsy","enrollment":153},{"nctId":"NCT06425991","phase":"PHASE1","title":"A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-06-07","conditions":"Relapsed or Refractory Multiple Myeloma","enrollment":108},{"nctId":"NCT05862285","phase":"PHASE3","title":"A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-06-01","conditions":"Cancer","enrollment":100},{"nctId":"NCT03523442","phase":"PHASE1","title":"A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-08-31","conditions":"Prostatic Neoplasms","enrollment":19},{"nctId":"NCT01900743","phase":"PHASE2","title":"Phase II Study of Regorafenib in Metastatic Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2013-06-05","conditions":"Sarcoma","enrollment":219},{"nctId":"NCT04590963","phase":"PHASE3","title":"Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-10-02","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":370},{"nctId":"NCT07128524","phase":"PHASE2","title":"Ketones for Opioid Craving","status":"NOT_YET_RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2026-05","conditions":"Opioid Use Disorder","enrollment":50},{"nctId":"NCT02592317","phase":"PHASE1","title":"A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2016-02-12","conditions":"Prostatic Neoplasms, Castration-Resistant","enrollment":23},{"nctId":"NCT06550895","phase":"PHASE2","title":"A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-09-16","conditions":"Multiple Myeloma","enrollment":11},{"nctId":"NCT06382948","phase":"PHASE3","title":"Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.","status":"RECRUITING","sponsor":"MedSIR","startDate":"2024-12-05","conditions":"Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":240},{"nctId":"NCT07466875","phase":"NA","title":"Auricular Stimulation for Nicotine Withdrawal in Psychiatric Inpatients","status":"NOT_YET_RECRUITING","sponsor":"Chiao-Chiao Liao","startDate":"2026-04-01","conditions":"Nicotine Dependence, Nicotine Withdrawal, Tobacco Use Disorder","enrollment":60},{"nctId":"NCT05744375","phase":"PHASE2","title":"Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab","status":"TERMINATED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2023-09-28","conditions":"Locally Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":2},{"nctId":"NCT07467590","phase":"PHASE2","title":"Combination of High and Low-Dose Radiotherapy With Immune Therapy and TKI in Advanced Colorectal Cancer: A Phase II Study","status":"NOT_YET_RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2026-04-01","conditions":"Refractory Colorectal Cancer, Radiotherapy-Induced Immune Priming, Immune Response","enrollment":33},{"nctId":"NCT05884398","phase":"PHASE3","title":"A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-08-31","conditions":"Metastatic Castrate-sensitive Prostate Cancer","enrollment":420}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1907,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"treatment withdrawal","genericName":"treatment withdrawal","companyName":"University Hospital, Strasbourg, France","companyId":"university-hospital-strasbourg-france","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Withdrawal treatment involves the use of medications to help manage withdrawal symptoms in individuals who are dependent on substances such as opioids, alcohol, or benzodiazepines. Used for Management of opioid withdrawal symptoms, Prevention of opioid relapse.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}